Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial - Full Text View

Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial

This study has been completed.

Sponsored by:	Universita di Verona
Information provided by:	Universita di Verona
ClinicalTrials.gov Identifier:	NCT00512187

Purpose

The study hypothesis is to investigate whether a moderate weight loss (i.e. a weight reduction of at least 5%) could improve the response rate to a suboptimal dose of cyclosporine in patients with severe psoriasis.

Condition	Intervention	Phase
Chronic Plaque Psoriasis Obesity	Other: low calorie diet	Phase IV

MedlinePlus related topics:

Obesity Psoriasis Weight Control

ChemIDplus related topics:

Cyclosporine Cyclosporin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial

Further study details as provided by Universita di Verona:

Primary Outcome Measures:

Primary end point PASI 75 response [ Time Frame: week 24 ]

Secondary Outcome Measures:

secondary end point was % of body weight reduction [ Time Frame: week 24 ]

Study Start Date:	November 2005
Study Completion Date:	August 2007

Arms	Assigned Interventions
first group: Experimental patients who adhered to a low-calorie diet associated to sub-optimal cyclosporine dose (2.5 mg/Kg/day)for 24 weeks	Other: low calorie diet Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 years of age,active but clinically stable plaque psoriasis involving at least 10 percent of the body surface area and a psoriasis area and severity index (PASI) score ≥10 and a body mass index ≥30.

Exclusion Criteria:

Other type of psoriasis (guttate, erythrodermic and pustular psoriasis)
Uncontrolled hypertension
Severe congestive heart failure
Renal and liver impairment
Active or chronic infections, including HIV, HBV and HCV infections, latent tuberculosis
Previous or active malignancies
Pregnancy and lactations
Previous treatment with cyclosporine
Phototherapy or any systemic or topical therapy for psoriasis within the previous 4 weeks before enrolment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00512187

Locations


Italy
	University of Verona
	Verona, Italy, 37126

Sponsors and Collaborators

Universita di Verona

Investigators


Principal Investigator:	Giampiero Girolomoni	University of Verona, Section of Dermatology and Venereology

More Information

Study ID Numbers:	GISONDI 1, no grants received at all
First Received:	August 6, 2007
Last Updated:	August 6, 2007
ClinicalTrials.gov Identifier:	NCT00512187
Health Authority:	Italy: Ethics Committee

Study placed in the following topic categories:

Body Weight

Signs and Symptoms

Obesity

Cyclosporine

Skin Diseases

Psoriasis

Weight Loss

Nutrition Disorders

Overweight

Overnutrition

Cyclosporins

Skin Diseases, Papulosquamous

Additional relevant MeSH terms:

Immunologic Factors

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Enzyme Inhibitors

Immunosuppressive Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 10, 2008